276 related articles for article (PubMed ID: 25393367)
1. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Yang H; Lan P; Hou Z; Guan Y; Zhang J; Xu W; Tian Z; Zhang C
Br J Cancer; 2015 Jan; 112(1):112-21. PubMed ID: 25393367
[TBL] [Abstract][Full Text] [Related]
2. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
Srinivas C; Swathi V; Priyanka C; Anjana Devi T; Subba Reddy BV; Janaki Ramaiah M; Bhadra U; Bhadra MP
Apoptosis; 2016 Nov; 21(11):1249-1264. PubMed ID: 27502208
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
Humphreys KJ; Cobiac L; Le Leu RK; Van der Hoek MB; Michael MZ
Mol Carcinog; 2013 Jun; 52(6):459-74. PubMed ID: 22308110
[TBL] [Abstract][Full Text] [Related]
4. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
Goto K; Annan DA; Morita T; Li W; Muroyama R; Matsubara Y; Ito S; Nakagawa R; Tanoue Y; Jinushi M; Kato N
Sci Rep; 2016 Dec; 6():38407. PubMed ID: 27910927
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
Wang Y; Zhu Q; Hu H; Zhu H; Yang B; He Q; Yu L; Zeng S
Biochem Pharmacol; 2021 Jun; 188():114546. PubMed ID: 33838133
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells.
Li JY; Tian T; Han B; Yang T; Guo YX; Wu JY; Chen YS; Yang Q; Xie RJ
World J Gastroenterol; 2023 Sep; 29(34):5038-5053. PubMed ID: 37753370
[TBL] [Abstract][Full Text] [Related]
8. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
Henrici A; Montalbano R; Neureiter D; Krause M; Stiewe T; Slater EP; Quint K; Ocker M; Di Fazio P
Mol Carcinog; 2015 Aug; 54(8):585-97. PubMed ID: 24375802
[TBL] [Abstract][Full Text] [Related]
9. CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.
Yang PM; Lin PJ; Chen CC
Epigenetics; 2012 Apr; 7(4):390-9. PubMed ID: 22419072
[TBL] [Abstract][Full Text] [Related]
10. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
11. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition regulates miR-449a levels in skeletal muscle cells.
Poddar S; Kesharwani D; Datta M
Epigenetics; 2016 Aug; 11(8):579-87. PubMed ID: 27184529
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs.
Kishikawa T; Otsuka M; Yoshikawa T; Ohno M; Takata A; Shibata C; Kondo Y; Akanuma M; Yoshida H; Koike K
Sci Rep; 2013; 3():2739. PubMed ID: 24061441
[TBL] [Abstract][Full Text] [Related]
14. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC.
Zhao ZN; Bai JX; Zhou Q; Yan B; Qin WW; Jia LT; Meng YL; Jin BQ; Yao LB; Wang T; Yang AG
PLoS One; 2012; 7(9):e45133. PubMed ID: 23028803
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
Di Fazio P; Montalbano R; Neureiter D; Alinger B; Schmidt A; Merkel AL; Quint K; Ocker M
Exp Cell Res; 2012 Sep; 318(15):1832-43. PubMed ID: 22683924
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
Kunnimalaiyaan S; Sokolowski K; Gamblin TC; Kunnimalaiyaan M
Am J Surg; 2017 Apr; 213(4):645-651. PubMed ID: 28007318
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.
You BR; Park WH
Mol Carcinog; 2017 Dec; 56(12):2566-2577. PubMed ID: 28667779
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Shi Y; Jia Y; Zhao W; Zhou L; Xie X; Tong Z
Int J Mol Med; 2018 Jul; 42(1):435-442. PubMed ID: 29620153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]